Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $169.10M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
Returns on capital
Korro Bio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-228.0%
avg -27.9%
ROIC
-83.8%
avg -51.8%
ROA
-103.3%
avg -51.7%
Analysis
ROIC is currently the strongest return metric at -83.8% versus its period average of -51.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ram Aiyar | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer & Director | USD 852.66K | 48 | 69.05K | 0.69% |
Loic Vincent | Chief Scientific Officer | USD 642.52K | — | — | — |
Jeffrey Cerio | Senior Vice President, General Counsel & Corporate Secretary | USD 587.5K | — | 41.79K | 0.42% |
Jean-Francois Formela | Co-Founder & Director | USD 51.5K | 69 | 121.22K | 1.22% |
Andrew Fraley | Co-Founder & Advisor | — | — | — | — |
Joshua Rosenthal | Co-Founder & Advisor | — | — | — | — |
Gaozhong Zhu | SVP of Chemistry, Manufacturing and Controls & Technical Operations | — | — | — | — |
Oliver Dolan | Senior Vice President of Finance & Principal Accounting Officer | — | 43 | 16.24K | 0.16% |
Todd Chappell | Chief Operating Officer | — | 53 | 24.46K | 0.25% |
Stephanie Engels | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
25
$21.68M
Sells
39
$6.67M
Net Transaction Value
+$15.01M
Net buying
Most Active
FORMELA JEAN FRANCOIS
30 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 12, 26Nov 12, 2026 | FORMELA JEAN FRANCOIS Indirect | Sell | $474.4K$474,402.50 |
| Nov 12, 26Nov 12, 2026 | FORMELA JEAN FRANCOIS Indirect | Sell | $98.2K$98,241.00 |
| Nov 11, 26Nov 11, 2026 | FORMELA JEAN FRANCOIS Indirect | Sell | $46.6K$46,550.40 |
| Nov 11, 26Nov 11, 2026 | FORMELA JEAN FRANCOIS Indirect | Sell | $285.6K$285,630.00 |
| Nov 11, 26Nov 11, 2026 | FORMELA JEAN FRANCOIS Indirect | Sell | $59.2K$59,160.00 |
| Nov 11, 26Nov 11, 2026 | FORMELA JEAN FRANCOIS Indirect | Sell | $9.6K$9,625.20 |
| Oct 26, 26Oct 26, 2026 | Lynx1 Capital Management LP Indirect | Buy | $295.1K$295,091.43 |
| Oct 23, 26Oct 23, 2026 | Lynx1 Capital Management LP Indirect | Buy | $30.4K$30,386.31 |
| Oct 22, 26Oct 22, 2026 | Lynx1 Capital Management LP Indirect | Buy | $441.5K$441,464.00 |
| Oct 22, 26Oct 22, 2026 | Lynx1 Capital Management LP Indirect | Buy | $117.8K$117,810.17 |
1–10 of 64
Summary
Insiders reported 25 buys worth $21.68M and 39 sells worth $6.67M over the last 12 months. That adds up to net buying of $15.01M. FORMELA JEAN FRANCOIS was the most active insider with 30 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +30.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +30.3% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Korro Bio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about KRRO's management, answered from reported figures.
Who manages KRRO?
Korro Bio, Inc. (KRRO) lists 10 active executives. The top listed executive is Andrew Fraley, Co-Founder & Advisor.
Are KRRO insiders buying or selling?
Recent insider activity shows net buying of $49.17M.
Continue the stock analysis
Jump to another research area for this company.